← boardnext 2027-04-30next 2030-12-01
RLAY
Relay Therapeutics, Inc.distress 6/10 · elevated risk$18.81-2%today-9% from 52w high
Oncology 1
Lead: PIK3CA Mutation · target HER2
Revenue
pre-revenue
Liquidity
$205M
Runway
1.0 yrs
Shares 1y
+11%
Price & events
+147.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-2.9%
1W
+7.9%
1M
+24.7%
3M
+153.2%
6M
+396.3%
1Y
+98.4%
2Y
-45.1%
5Y
-53.5%
All
Overview
- Market Cap
- $3.60B
- Volume
- 128.21K
- 52 Week Range
- $3.22 – $20.75
- Total Shares
- 191.59M
- Float Shares
- 136.14M
- Short %
- 23.02%
- % Held by Insiders
- 1.37%
- % Held by Institutions
- 87.14%
- RVOL
- 0.03x
- Beta
- 1.68
Pipeline stages · 2 programs
RLY-2608
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RTx-021
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04-30 Estimated 50% readout ~2027-05-30 | Phase 1 | RLY-2608, Fulvestrant, Palbociclib 125mg | PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor | — | recruiting |
| 2027-12-30 Estimated 50% readout ~2028-01-29 | Phase 1 | RLY-8161 | Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D, NRAS G13R, NRAS G13D, NRAS G12V, NRAS Q61R, NRAS Q61K, NRAS Q61L, NRAS Q61H | — | recruiting |
| 2028-04-30 Estimated 50% readout ~2028-07-14 | Phase 3 | RLY-2608, Capivasertib, Fulvestrant | PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | — | recruiting |
| 2030-12-01 Estimated 50% readout ~2031-01-15 | Phase 1/2 | RTx-021 | Stargardt Disease | — | recruiting |
| 2031-07 Estimated 50% readout ~2031-08-15 | Phase 2 | RLY-2608 | PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP), Vascular Anomalies | — | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-18 | Phase 1 | RLY-5836, Fulvestrant, Palbociclib | PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor | 41 | completed |
Catalyst news & presentations · 14
- early 2027Guided 70%trial initiationsecondaryPhase 3zovegalisib · Phase 3 trial of zovegalisib + atirmociclib + aromatase inhibitor in 1L endocrine sensitive patientsSEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- 2026-04-27partnershipzovegalisib · Pfizer supply agreement for atirmociclib in planned Phase 3 trialSEC 8-K
- March 16, 2026conferencedata presentationsecondaryPhase 1/2zovegalisib · Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed dose in CDK4/6-experienced patients.SEC 8-K
- 2H 2025trial initiationsecondarynon-inhibitory alphaGal chaperone · Clinical start for non-inhibitory chaperone for Fabry disease.SEC 8-K
- 2025trial initiationsecondaryRLY-2608 · Planned initiation of pivotal 2L study.SEC 8-K
- 2025readoutPhase 1/2RLY-2608 · Full Phase 1/2 data for RLY-2608.SEC 8-K
- 2H 2025trial initiationsecondaryNRAS-selective inhibitor · Clinical start for NRAS-selective inhibitor.SEC 8-K
- mid-2025trial initiationsecondaryPhase 3zovegalisib (RLY-2608) · Phase 3 ReDiscover-2 trial initiatedSEC 8-K
- first half of 2025enrollment completesecondaryRLY-2608 · Triplet combination with ribociclib expected to move into dose expansion in 1H 2025.SEC 8-K
- 1Q 2025trial initiationsecondaryRLY-2608 · Clinical start for RLY-2608 in vascular malformations.SEC 8-K
- October 23-25, 2024conferencedata presentationsecondaryLirafugratinib · Updated FGFR2 fusion data at AACR-NCI-EORTC conference.SEC 8-K
- 2024-09-09fda agreementLirafugratinib · FDA suggested file NDA in cholangiocarcinoma first, then tumor agnostic sNDA.SEC 8-K
- September 9, 2024conferencedata presentationsecondaryRLY-2608 · Conference call to discuss interim data from ReDiscover trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $25 (+35% upside) · 13 analysts
- 2026-07-21Goldman SachsBuy
- 2026-07-16Canaccord GenuityBuy
- 2026-07-08JP MorganOverweight
- 2026-05-26GuggenheimBuy
- 2026-05-26HC Wainwright & Co.Buy
- 2026-05-20CitizensMarket Outperform
Competitors — HER2
Recent news
- 2026-07-21Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise - Stock Titan
- 2026-07-21RLAY Maintained by Goldman Sachs -- Price Target Raised to $31 - GuruFocus
- 2026-07-21RLAY Maintained by Goldman Sachs -- Price Target Raised to $31 - GuruFocus
- 2026-07-21Relay Therapeutics stock trades around recent lows as cash burn and pipeline data shape the outlook - Ad-hoc-news.de
- 2026-07-20Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
- 2026-07-20Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
- 2026-07-16Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com
- 2026-07-16RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.